Toxoplasma gondii infection and schizophrenia: An inter-kingdom communication perspective

Current Opinion in Infectious Diseases

Volumn 29, Issue 3, 2016, Pages 311-318

  Elsheikha, Hany M ^a   Zhu, Xing Quan ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

host pathogen interaction; inter kingdom signaling; schizophrenia; Toxoplasma gondii

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIPROTOZOAL AGENT; ARGIPRESSIN; C REACTIVE PROTEIN; DOPAMINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; NEUROTRANSMITTER;

AAH1 GENE; AAH2 GENE; ADAPTATION; BRAIN CELL; BRAIN TISSUE; CELL FUNCTION; DOPAMINE RELEASE; DRUG EFFICACY; EPIGENETICS; GENE; HOST PARASITE INTERACTION; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; INTRACELLULAR SIGNALING; META ANALYSIS (TOPIC); NERVE CELL LESION; NONHUMAN; PARASITE CLEARANCE; PATHOGENESIS; PROTEIN BLOOD LEVEL; REVIEW; SCHIZOPHRENIA; TOXOPLASMA GONDII; TOXOPLASMOSIS; BRAIN; COMPLICATION; HOST PATHOGEN INTERACTION; METABOLISM; PARASITOLOGY; PATHOPHYSIOLOGY; TOXOPLASMA;

BRAIN; DOPAMINE; HOST-PATHOGEN INTERACTIONS; HUMANS; SCHIZOPHRENIA; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84966322366     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000265     Document Type: Review

References (57)

1. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167:261-280.
2. Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res 2003; 62:237-244.
3. Flegr J. Effects of toxoplasma on human behavior. Schizophr Bull 2007; 33:757-760.
4. Brooks JM, Carrillo GL, Su J, et al. Toxoplasma gondii infections alter GABAergic synapses and signaling in the central nervous system. mBio 2015; 6: e01428-15.
5. Stibbs HH. Changes in brain concentrations of catecholamines and indo-leamines in Toxoplasma gondii infected mice. Ann Trop Med Parasitol 1985; 79:153-157.
6. Gaskell EA, Smith JE, Pinney JW, et al. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS One 2009; 4:e4801.
7. Prandovszky E, Gaskell E, Martin H, et al. The neurotropic parasite Toxoplasma gondiiincreases dopamine metabolism. PLoS One 2011; 6:e23866.
8. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002; 303:1-10.
9. Notarangelo FM, Wilson EH, Horning KJ, et al. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. Schizophr Res 2014; 152:261-267.
10. Lim A, Kumar V, Hari Dass SA, Vyas A. Toxoplasma gondii infection enhances testicular steroidogenesis in rats. Mol Ecol 2013; 22:102-110.
11. Hari Dass SA, Vyas A. Toxoplasma gondii infection reduces predator aversion in rats through epigenetic modulation in the host medial amygdala. Mol Ecol 2014; 23:6114-6122.
12. Holub D, Flegr J, Dragomirecka E, et al. Differences in onset of disease and severity of psychopathology between toxoplasmosis-related and toxo-plasmosis-unrelated schizophrenia. Acta Psychiatr Scand 2013; 127:227-238.
13. Eells JB, Varela-Stokes A, Guo-Ross SX, et al. Chronic Toxoplasma gondii in Nurr1-Null heterozygous mice exacerbates elevated open field activity. PLoS One 2015; 10:e0119280.
14. Carter CJ. Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii. Schizophr Bull 2009; 35:1163-1182.
15. Berenreiterova M, Flegr J, Kubena AA, Nemec P. The distribution of Toxoplasma gondii cysts in the brain of a mouse with latent toxoplasmosis: implications for the behavioral manipulation hypothesis. PLoS One 2011; 6:e28925.
16. Evans AK, Strassmann PS, Lee IP, Sapolsky RM. Patterns of Toxoplasma gondii cyst distribution in the forebrain associate with individual variation in predator odor avoidance and anxiety-related behavior in male Long-Evans rats. Brain Behav Immun 2014; 37:122-133.
17. Flegr J. Influence of latent Toxoplasma infection on human personality, physiology and morphology: pros and cons of the Toxoplasma-human model in studying the manipulation hypothesis. J Exp Biol 2013; 216:127-133.
18. Miller CM, Boulter NR, Ikin RJ, Smith NC. The immunobiology of the innate response to Toxoplasma gondii. Int J Parasitol 2009; 39:23-39.
19. Webster JP, Lamberton PH, Donnelly CA, Torrey EF. Parasites as causative agents of human affective disorders? The impact of antipsychotic, mood-stabilizer and antiparasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc Biol Sci 2006; 273:1023-1030.
20. Goodwin DG, Strobl JS, Lindsay DS. Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures. J Parasitol 2011; 97:148-151.
21. Strobl JS, Goodwin DG, Rzigalinski BA, Lindsay DS. Dopamine stimulates propagation of Toxoplasma gondii tachyzoites in human fibroblast and primary neonatal rat astrocyte cell cultures. J Parasitol 2012; 98:1296-1299.
22. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull 2007; 33:729-736.
23. Wang ZT, Harmon S, O'Malley KL, Sibley LD. Reassessment of the role of aromatic amino acid hydroxylases and the effect of infection by Toxoplasma gondii on host dopamine. Infect Immun 2015; 83:1039-1047.
24. Naemat A, Elsheikha HM, Boitor RA, Notingher I. Tracing amino acid exchange during host-pathogen interaction by combined stable-isotope time-resolved Raman spectral imaging. Sci Rep 2016; 6: 20811.
25. McConkey GA, Peers C, Prandovszky E. Reproducing increased dopamine with infection to evaluate the role of parasite-encoded tyrosine hydroxylase activity. Infect Immun 2015; 83:3334-3335.
26. Wang ZT, Sibley LD. Reply to'reproducing increased dopamine with infection to evaluate the role of parasite-encoded tyrosine hydroxylase activity'. Infect Immun 2015; 83:3336-3337.
27. Suzuki Y, Claflin J, Wang X, et al. Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplas-ma gondii. Int J Parasitol 2005; 35:83-90.
28. Mahmoud ME, Ihara F, Fereig RM, et al. Induction of depression-related behaviors by reactivation of chronic Toxoplasma gondii infection in mice. Behav Brain Res 2016; 298 (pt B):125-133.
29. Schwarcz R, Rassoulpour A, Wu HQ, et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50:521-530.
30. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2, 3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005; 49:15-23.
31. Goff DC. Drug development in schizophrenia: are glutamatergic targets still worth aiming at? Curr Opin Psychiatry 2015; 28:207-215.
32. Kegel ME, Bhat M, Skogh E, et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res 2014; 7:15-22.
33. Zhou CX, Zhou DH, Elsheikha HM, et al. Global metabolomic profiling of mice brains following experimental infection with the cyst-forming Toxoplasma gondii. PLoS One 2015; 10:e0139635.
34. Fuks JM, Arrighi RBG, Weidner JM, et al. GABAergic signaling is linked to a hypermigratory phenotype in dendritic cells infected by Toxoplasma gondii. PLoS Pathog 2012; 8:e1003051.
35. Blanchard N, Dunay IR, Schluter D. Persistence of Toxoplasma gondii in the central nervous system: a fine-tuned balance between the parasite, the brain and the immune system. Parasite Immunol 2015; 37:150-158.
36. Li H, Gang Z, Yuling H, et al. Different neurotropic pathogens elicit neurotoxic CCR9-or neurosupportive CXCR3-expressing microglia. J Immunol 2006; 177:3644-3656.
37. Fabiani S, Pinto B, Bonuccelli U, Bruschi F. Neurobiological studies on the relationship between toxoplasmosis and neuropsychiatric diseases. J Neurol Sci 2015; 351:3-8.
38. Tomasik J, Schultz TL, Kluge W, et al. Shared immune and repair markers during experimental Toxoplasma chronic brain infection and schizophrenia. Schizophr Bull 2015; pii:sbv134.
39. Horacek J, Flegr J, Tintera J, et al. Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: voxel-based-morphometry (VBM) study. World J Biol Psychiatry 2012; 13:501-509.
40. Sun GY, Horrocks LA, Farooqui AA. The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegen-erative diseases. J Neurochem 2007; 103:1-16.
41. Dugan LL, Ali SS, Shekhtman G, et al. IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase. PLoS One 2009; 4:e5518.
42. Tan HY, Nicodemus KK, Chen Q, et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008; 118:2200-2208.
43. Bougdour A, Durandau E, Brenier-Pinchart MP, et al. Host cell subversion by Toxoplasma GRA16, an exported dense granule protein that targets the host cellnucleus andalters geneexpression. Cell Host Microbe 2013;13:489-500.
44. Saeij JP, Boyle JP, Coller S, et al. Polymorphic secreted kinases are key virulence factors in toxoplasmosis. Science 2006; 314:1780-1783.
45. Ong YC, Reese ML, Boothroyd JC. Toxoplasma rhoptry protein 16 (ROP16) subverts host function by direct tyrosine phosphorylation of STAT6. J Biol Chem 2010; 285:28731-28740.
46. Koshy AA, Dietrich HK, Christian DA, et al. Toxoplasma co-opts host cells it does not invade. PLoS Pathog 2012; 8:e1002825.
47. Schneider AG, Abi Abdallah DS, Butcher BA, Denkers EY. Toxoplasma gondii triggers phosphorylation and nuclear translocation of dendritic cell STAT1 while simultaneously blocking IFNg-induced STAT1 transcriptional activity. PLoS One 2013; 8:e60215.
48. Vyas A, Kim SK, Giacomini N, et al. Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc Natl Acad Sci USA 2007; 104:6442-6447.
49. Clark RT, Nance JP, Noor S, Wilson EH. T-cell production of matrix metalloproteinases and inhibition of parasite clearance by TIMP-1 during chronic Toxoplasma infection in the brain. ASN Neuro 2011; 3:e00049.
50. Okulski P, Jay TM, Jaworski J, et al. TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol Psychiatry 2007; 62:359-362.
51. Hinze-Selch D, Dä ubener W, Eggert L, et al. A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence. Schizophr Bull 2007; 33:782-788.
52. Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 2007; 93:261-265.
53. Vyas A. Extended epigenotype in a Rattus novergicus-Toxoplasma gondii association. Commun Integr Biol 2015; 8:e992743.
54. Conejero-Goldberg C, Torrey EF, Yolken RH. Herpesviruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients. Schizophr Res 2003; 60:65-69.
55. Fond G, Macgregor A, Tamouza R, et al. Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci 2014; 264:79-183.
56. Fond G, Boyer L, Gaman A, et al. Treatment with antitoxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: a cross-sectional study. J Psychiatr Res 2015; 63:58-64.
57. Shibre T, Alem A, Abdulahi A, et al. Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Schizophr Bull 2010; 36:846-851.